NPEW 2025: Gencor introduces Trpti for weight management, metabolic, and microbiome health
31 Mar 2025 | Gencor
At the recent Natural Products Expo West (NPEW) 2025 trade show, Gencor unveiled Trpti, a new fatty acid ethanolamide designed to support weight management and metabolic health. Co-founder Ramasamy Venkatesh spoke with us about the ingredient's role as a natural GLP-1 activator, its mechanisms of action, and its effects on metabolism and the gut microbiome. At the same time, Maggie McNamara, the company’s marketing director, highlighted its versatility and the expanding market for GLP-1 complement products.
This is Yolanda von Hall from Nutrition Insight.
I'm here at Natural Products Expo West 2025 with Genkar, McNamara, and Venat.
Thank you both for joining us today.
And we understand that you're launching or you've launched a new product, TEA, and I'm just really curious what inspired you to develop it and what market developments that you see does it respond to.
We developed Tripty because we identified a demand in the market.
As you know, a lot of people are talking about GLP one and it's a very, very popular term and trend in the market.
Tripty is OEA which is a natural.
GLP1 activated.
So instead of us creating something that would be a foreign substance to the body, OEA is a natural substance to the body and basically what it does is it naturally activates GLP-1 in the body.
And we saw that there was definitely a need in the body.
For something natural that wasn't going to cause massive side effects when people were taking it.
It wasn't going to cause problems.
It was going to help with your digestion and help with your probiotics in your body, and so we're very excited about launching our trip to at the show.
Awesome.
And I'm also curious if you.
You can explain a bit the unique mechanism of action behind tripti and how it differs from traditional weight management ingredients.
OEA, short form for oleol etanolamide, and tripti is our brand which is OEA potentiated by our lipids first delivery system.
OEA is naturally produced in the body.
In response to diet, OK, and it's produced in the intestine mainly, mainly, and it, it then binds to a receptor called GPR 119 and releases GLP-1, and this happens instantaneously in response to 3D.
That's how.
The body's own natural GLP-1 is produced in response to eating, and it takes care of all your metabolic health, like glucose metabolism, lipid metabolism, weight management, satiety, fat management, all those areas.
OK.
Now, the challenges are that when you're young, that's why you eat and drink what you want, but you're in the prime of health.
Your intestinal health is good.
You've got a, good microbiome, which takes care of the whole process and such.
But, pollution, processed food, pro-inflammatory substances, eating, drinking, smoking, drinking, all these put together that negatively impacting gut health, and that creates imbalances in the production of OEA and the release of OEA and the binding and then the subsequent release of GLP-1.
So we found that, OK, this is the key reason why metabolic imbalances occur.
There are multiple reasons, but this is one of the key reasons.
And it's directly related to weight, fat management, die, lipid, and glucose metabolism.
So why don't we look at a solution for that?
And we studied and found that OEA does this naturally in the body, but OEA is basically made from oleic acid, and it's got a double bond.
It's a monounsaturated fatty acid which becomes a monounsaturated fatty acid in the body.
And that gets hydrolyzed and degraded very easily in your gastrointract.
It needed to be delivered to the intestines to be effective.
So we then have the lipid first delivery system of our sister company Pharmaco Biotechnology through which we found that we could deliver it effectively.
And that is how this whole thing came up.
We understood how it works.
We understood where it needs to be delivered, and then we ended up delivering it and we got clinical data backing it.
Awesome, so interesting.
And the Lippy Spurs technology.
I'm also curious if you can talk a bit about how does Lippy Spur's technology enhance the bioavailability and effectiveness compared to conventional OEA because you've already explained a little bit.
Can you dive in a little bit more detail there.
It gets hydrolyzed, very fast and it's also destroyed by fatty acidamide hydrolyse, which is everywhere in the body.
So it needs to be shepherded down to the right area to act.
The lipid per delivery system is basically a lipid delivery system.
Basically, OE is still a fatty acidamide.
It's a lipid.
So, Lipid particles normally have difficulty in being absorbed by the body because they clump up and they present a low surface area for absorption and it's challenging to get them through the GI tract and get it.
What the lipor delivery system is, lipid dispersion system.
OK, by scoring.
The active with the lipids technology, what it does is it creates a repulsive sort of an attractive forces in between the OEA particles, and it lowers the surface of water.
So when the OEA with lipid spurt hits the aqued layer, not only do the particles repel, they also.
Lower the surface tension of water and each molecule of oil is surrounded by a molecule of water that shepherds it through the gastrointestinal front and then takes it into the intestines for delivery.
The intestines also the absorption happens due to the intestine and villa which are hills and valleys.
These hills and valleys are again supported by a layer of mucosa.
So for a normal lipid, even if a normal OE reaches there, again, the water particles repel lipids.
So again, there's a secondary layer of repulsion, but because each molecule of OE is surrounded by a molecule of water that acts like a Trojan horse, and it increases the absorption into the intestine because of which we're able to deliver it effectively to the intestine where it can act better.
Awesome.
Interesting, and I'm curious, you've mentioned already some studies.
What have studies revealed about the optimal dosage of trippy and how that dose impacts weight management outcomes?
Yeah, so right now we have we have completed a study on 300 MBA of OEA with lipids containing not less than 250 MB of OEA on the microbiome because one of the published data.
Which shows with the existing sciences that OEA upregulates 23 bacteria which is Achimansia mucinopilla and bacteria, of bacteria thrastoi.
Both of them are involved in immunity, metabolic function, production of short chain fatty acids, and weight management, resulting in weight management and fat management, and these are the bacteria.
Which take care of it when you're healthy and while published science shows that this is the proposed mechanism of action with in vitro animal data, we actually did it in a human study and we have shown that these two bacteria are getting up.
Plus, inflammation markers like IL-1 beta and IL-2 are coming down, OK, because intestinal inflammation is one of the major challenges always to maintain, the gut integrity of the microbiome because many of the, tight junctions like zonin, o, laudin.
They don't remain tight and the exoskeleton and the bacterial LPS from the bacteria leaks into the intestines and creates inflammation, creates problems.
Here we've shown that some of these, tight junctions integrity is maintained and the microbiome basically got populated by the more efficient bacteria.
So that is one thing.
Second thing, what we saw is the GLP-1 levels went up.
OK, now, GLP1, as you know, is.
Produced in response to diet and it acts instantaneously.
So we just completed a pilot study of a few people to look at the proof of concept and looked at with OEA and without OEA with food and looked at response 2 hours, 4 hours, 6 hours, 8 hours.
Two things are happening.
GLP-1 levels are going up significantly and GIP levels are coming down.
There are two ways by which.
Insulin constipation is managed by your body.
One is by GLP1.
Another is by GIP.
Both of them basically induce, diet induced, affect diet induced insulin production.
But with GIP what's happening is that it also breaks down the fats into the unwanted adipose fats.
OK, it breaks down triglycerides into adipose fat, and it's stores, so you put on weight, a lot of the tri glucose, dependent medicines, especially sulfonylurea, you end up putting on weight.
They act on this manner and you end up then putting on the back fat, which is the adipose fat.
What we've seen is the GLP1 went up and GLP1 came down.
So number one, you are.
Activity of metabolism, which is mediated by GLP-1, it's increasing one, and then the GLP-1 going down helps reduce shortage of onwards.
That is being reflected in the actual study.
Now we'll be doing more studies.
We're working on planning for, we are not currently doing a larger study on 300 mg as as half dose of 150 mg to look at GLP-1 and GIP.
We're also designing, weight loss and glucose control and fat studies.
A lot of this is in process because what we're doing is validating the mechanism of action.
You know that once GLP1 increases, the rest is going to follow.
That's exactly what we're doing.
OK, interesting.
And Maggie, can you talk a little bit of how, how you envision TRI's application in functional food and beverages.
The wonderful thing about Tripty is that it is OEA combined with Lippy Spru, and Lippy Spru being the incredible delivery technology that it is, not only does it help its bioavailability, but it also increases the format in which manufacturers and brands can offer that product.
So, into beverages, into foods, into gummies, into.
OTD shots, it's the format is huge when we have something like Lippy Spurs driving the OEA.
So if we envision that it'll be included in a lot of products, in a lot of different formats, and we also envision that it'll be combined with a lot of other products too to help with weight loss society and weight management.
Awesome, thank you both.
And I just want to add one last point today.
There's a lot of noise regarding GLP-1.
Genco, we come from a pharmaceutical background, so we understand this fully.
We started as a pharma company and we still do a lot of pharmaceuticals, including the generic forms of liraglutide and semaglutide.
So these are GLP1.
Agonist basically act like GLP-1, but they give a lot of horrible side effects.
Terrible.
Now there's a whole industry developing now to develop nutraceuticals to mitigate the side effects.
We are very different.
We are the only one currently offering a solution to actually increase GLP1 and not an agonist, give back to your body what it does the best naturally.
Good luck with the rest of the show.
Thank you.
